FDA Alert: FDA Requires Guillain-Barré Syndrome (GBS) Warning …
3 days ago · Arexvy was initially approved on May 3, 2023, for the prevention of LRTD caused by RSV in individuals 60 years of age and older. ... Subscribe to our newsletter for the latest …
RSV Vaccine Labeling Updated With Guillain-Barré Syndrome …
2 days ago · Arexvy is indicated for active immunization for the prevention of LRTD caused by RSV in individuals 60 years and older, and those 50 through 59 years old at increased risk for …
FDA Requires Warning for Guillain-Barré Syndrome in Prescribing ...
3 days ago · The FDA has also required GSK to conduct a study evaluating the risk of GBS among 1.9 million adults 50 years of age and older vaccinated with Arexvy. 1 “FDA has further …
New data for Arexvy, GSK’s respiratory syncytial virus vaccine, …
Oct 24, 2024 · GSK plc (LSE/NYSE: GSK) today announced new preliminary data for Arexvy (respiratory syncytial virus vaccine, recombinant adjuvanted) in adults aged 18-49 at increased …
New Data for AREXVY, GSK’s Respiratory Syncytial Virus Vaccine, …
PHILADELPHIA, October 24, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced new preliminary data for AREXVY (Respiratory Syncytial Virus Vaccine, …
GSK presents positive data for AREXVY, its respiratory syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain …
GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial …
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain …
FDA Approves First Respiratory Syncytial Virus (RSV) Vaccine
Today, the U.S. Food and Drug Administration approved Arexvy, the first respiratory syncytial virus (RSV) vaccine approved for use in the United States. Arexvy is approved for the...
GSK Presents Positive Data for AREXVY, Its Respiratory
Oct 8, 2024 · AREXVY is the world’s first RSV vaccine and was approved based on exceptional efficacy in adults aged 60 and older including those who are at increased risk due to certain …
GSK's RSV Vaccine Arexvy Gets FDA Nod for Adults 50-59 Years
Jun 10, 2024 · Arexvy is currently approved in the United States, Europe, Japan and several other countries in adults aged 60 and more for the prevention of lower respiratory tract disease …